The largest-ever morbi-mortality study of treatments for chronic heart failure has shown that adding the specific heart rate lowering agent Procoralan® (ivabradine) to standard therapy significantly reduces the risk of death and hospitalisation for heart failure.1 Results from this new study, SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial), were presented today at the European Society of Cardiology1 in Stockholm and published in The Lancet.2
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/shift/44195/
